Neurophth Biotechnology Receives NMPA Approval for Phase I/II Gene Therapy Study
Neurophth Biotechnology Ltd, a leading gene therapy specialist based in China, has announced that it...
Shenzhen Core Medical Technology Secures RMB 200 Million in Series C+ Financing for Artificial Heart Tech
Shenzhen Core Medical Technology Co., Ltd, a leading Chinese manufacturer of artificial hearts, has reportedly...
Hainan Poly Pharm Wins Health Canada Approval for Generic Cytovene-IV (Ganciclovir)
Hainan Poly Pharm Co., Ltd (SHE: 300630), a China-based pharmaceutical company, has announced that it...
Zephyrm Bioscience Secures Over RMB 200 Million in Series B Financing for Stem-Cell Drug Development
Zephyrm Bioscience, a prominent stem cell drug developer headquartered in Suzhou, has reportedly secured more...
Legend Biotech and Janssen Partner with Novartis on Carvykti Manufacturing and Clinical Supply
Legend Biotech Corporation (NASDAQ: LEGN), a China-based biotech firm, and its US partner Janssen Pharmaceutical...
CanSino Biologics Receives NMPA Approval for Bivalent COVID-19 mRNA Vaccine
CanSino Biologics Inc., a leading Chinese vaccines specialist, has announced that it has received clinical...
JS InnoPharm Initiates Phase Ib Study of AURKA Inhibitor VIC-1911 for EGFR-TKI Resistant NSCLC
JS InnoPharm Ltd, a Shanghai-based pharmaceutical company, announced that the first patient has been dosed...
Simcere Pharmaceutical Group Reports 26.4% YOY Revenue Growth in 2022 Financials
Simcere Pharmaceutical Group (HKG: 2096), a China-based pharmaceutical company, has reported its financial results for...
Henlius Reports 97.2% YOY Revenue Growth in Q1 2023, Highlighted by Strong Sales of Hanquyou and HaiSiZhuang
China-based biopharmaceutical company Henlius (HKG: 2696) has released its financial report for the first quarter...
Hainan Introduces Management Regulations for Urgently Needed Import Drugs and Devices in Boao Lecheng
The Hainan provincial government has issued a Notice on the Management Regulations for Clinically Urgently...
Minghui Pharmaceutical’s MH004 Cream Shows Positive Results in Atopic Dermatitis Phase II Trial
China-based Minghui Pharmaceutical has unveiled positive top-line data from a Phase II trial of its...
AffaMed Therapeutics Gets NMPA Approval for Phase III Dextenza Study in Post-Ophthalmic Surgery
China-based AffaMed Therapeutics has announced that it has received approval from the National Medical Products...
NHC Proposes Updates to Access Standards for Class A and B Medical Equipment
The National Healthcare Commission (NHC) has released two proposed updates to the Access Standards for...
Harbour Biomed to Present Early Clinical Data for CTLA-4 Antibody Combo at AACR 2023
China-based Harbour Biomed (HKG: 2142) is set to release early clinical data for its CTLA-4...
RemeGen’s Disitamab Vedotin (RC48) Clears for Phase I Study in HER2-Positive Tumors
RemeGen Ltd (HKG: 9995), a biopharmaceutical company, has announced that it has received approval from...
Junshi Biosciences’ JS401 Receives NMPA Approval for Hyperlipidemia Clinical Trial
Junshi Biosciences (HKG: 1877, SHA: 688180), a leading China-based biopharmaceutical company, has announced that it...
Jiangxi Jemincare Group Secures Exclusive Rights to Promote MabPharm’s Biosimilar CMAB007
Jiangxi Jemincare Group, a China-based healthcare company, has entered into a licensing agreement with fellow...
Zhejiang Dian Diagnostics Partners with Meituan for Digital Healthcare Services Expansion
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a prominent medical diagnostics company based in China,...
Ocumension Therapeutics’ Zerviate NDA Accepted for Review by China’s NMPA
Ocumension Therapeutics (HKG: 1477), a leading Chinese ophthalmology specialist, has announced that the National Medical...
Pfizer and Sinopharm Expand Partnership to Enhance Drug Distribution and Lifecycle Solutions
US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced a strategic partnership with China-based Sinopharm...